← Back to screener

Krystal Biotech, Inc. KRYS

Rank #2205 · Nasdaq · $9.8B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
29.3
P/E
896.1
P/B
18.76
ROE
2.1%
Op. Margin
-216.2%
Debt Ratio
21%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E 896.1x, P/B 18.76x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆
Weak

ROE 2.1%. Ranks in the top 79% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 21%. Ranks in the top 13% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2017–$-0.0B$-0.0B$0.0B–655
2019–$-0.0B$-0.0B$0.0B–6
2020–$-0.0B$-0.0B$0.1B–5
2021–$-0.0B$-0.0B$0.2B–16
2023$0.0B$-0.1B$-0.1B$0.3B–12
2024$0.0B$-0.1B$-0.1B$0.6B–7
2025$0.1B$-0.1B$0.0B$0.5B-216.221

← See the full screener